|Videos|July 23, 2013
Episode 15 - SLE: Expectations As the Drug Market Evolves
Advertisement
Although currently limited, Michelle Petri, MD, MPH, explains that the drug market for treating systemic lupus erythematosus (SLE) is growing. Dr Petri explains that because SLE is a heterogeneous disease that manifests in patients in many different ways, new agents to treat SLE will be classified into a series of different categories.
Dr Petri continues the discussion by exploring the future roles of these new agents which leads the panelists into a conversation about the costs of these treatment options.
Hugh Fatodu, RPh, MBA, and Dr Petri conclude that without proper data that review the long-term outcomes of agents for the treatment of SLE, it is difficult to estimate any economic benefits or advantages.
Advertisement
Related to this article
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5